Role of Leukocyte- and Platelet-Rich Fibrin Membranes in Endoscopic Endonasal Skull Base Reconstruction

NCT ID: NCT03910374

Last Updated: 2021-10-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective investigation of the effectivity of L-PRF membranes for skull base reconstruction after endoscopic endonasal skull base surgery (transsphenoidal) versus classical closure techniques.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators want to demonstrate in a prospective, randomized trial including 220 patients undergoing endoscopic endonasal skull base surgery that the use of L-PRF is non-inferior to classical fibrin sealants.

Approximately 220 patients undergoing cranial surgery will be enrolled in this randomized, controlled, single-blinded multicenter study to evaluate the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cranial Sutures; Closure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled clinical trial
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
Participants stay masked during the trial, care provider and investigators are unblinded at the surgical procedure and from thereon

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Classical Treatment

In this arm, dural closure will be performed with the classical fibrine sealants.

Group Type PLACEBO_COMPARATOR

Dural closure

Intervention Type PROCEDURE

Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair

L-PRF

In this arm, dural closure will be performed with the autologous L-PRF

Group Type ACTIVE_COMPARATOR

Dural closure

Intervention Type PROCEDURE

Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dural closure

Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with lesions of the sellar/parasellar region
* Age \> 18 and \< 70 years
* Written informed consent
* Willingness to adhere to visit schedules

Exclusion Criteria

* Age \< 18 and \> 70 years
* Any underlying rhinological condition like nasal polyps, which may interfere with the obtained results
* Any disorder which might compromise the ability of a patient to give truly informed consent for participation in this study
* Enrollment in other investigational drug trial(s)
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Laura Van Gerven

Clinical professor, Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laura Van Gerven, prof

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AZ Sint-Jan

Bruges, , Belgium

Site Status RECRUITING

UZ Leuven

Leuven, , Belgium

Site Status RECRUITING

Fundació Clínic Per A La Recerca Biomèdica

Barcelona, , Spain

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laura Van Gerven, prof

Role: CONTACT

003216332342

Anais Van Hoylandt, MSc

Role: CONTACT

003216342012

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kato Speleman, MD

Role: primary

050 45 22 80

Laura Van Gerven, prof

Role: primary

003216 332342

Anais Van Hoylandt

Role: backup

003216342012

Cristobal Langdon, prof

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Coucke B, Van Hoylandt A, Jorissen M, Meulemans J, Decramer T, van Loon J, Vander Poorten V, Theys T, Van Gerven L. Leukocyte- and platelet-rich fibrin in endoscopic endonasal skull base reconstruction: study protocol for a multicenter prospective, parallel-group, single-blinded randomized controlled non-inferiority trial. Trials. 2023 Jul 31;24(1):488. doi: 10.1186/s13063-023-07492-w.

Reference Type DERIVED
PMID: 37525278 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

s61636

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.